Diabetic nephropathy in type 2 diabetes mellitus: prevention and treatment  by CHURCHILL, David N
3Hong Kong J Nephrol 2001;3(1):3-6. DN CHURCHILL
Diabetic nephropathy in type 2 diabetes mellitus: prevention
and treatment
David N CHURCHILL
Faculty of Health Sciences, Father Sean O'Sullivan Research Centre, St Joseph's Hospital-McMaster
University, Hamilton, Ontario, Canada.
R E V I E W
A R T I C L E




Hong Kong Journal of Nephrology, April 2001
INTRODUCTION
Patients with end-stage renal disease (ESRD) secondary
to diabetes mellitus have a much higher dialysis-
associated mortality rate than similar non-diabetic
patients (1). They also have higher morbidity rates,
particularly with respect to vascular complications. These
results have been described as abysmal for patients with
type 2 diabetes mellitus (2) and have focused attention
on interventions that might decrease the development
and progression of nephropathy.
Diabetes mellitus has become an increasingly important
cause for ESRD requiring renal replacement therapy. It
was responsible for 22% of cases of ESRD in Canada in
1990, with an increase to 30% in 1998 (1). A similar
trend was reported in Europe with an increase from 11%
to 17% between 1984 and 1992 (3).
Most of this increase is due to type 2 diabetes mellitus,
the prevalence of which increases with advancing age.
In 1993, in the United States, the prevalence of diabetes
was about 4%, 8% and 11% in those aged 45 to 54 years,
55 to 64 years and over 64 years, respectively (4). A cross-
sectional Hong Kong study revealed a standardized
prevalence of 9.5% in men and 10.2% in women aged
35 to 64 years (5).
The prevalence has also increased over time. In the
United States (4), the incidence of diabetes increased,
among those aged 55 to 64 years, from 3% in 1958 to
8% in 1993 while for those aged over 64 years the
increase was from 4 to 11%. This increased prevalence
with time may be related to improved diagnosis and to
better cardiovascular care with some of the survivors
developing diabetic nephropathy. The increased
prevalence of type 2 diabetes mellitus is greater among
African Americans and Mexican Americans than
European Americans (6). Among First Nations
(aboriginal) people in Canada in 1997, the prevalence
of diabetes mellitus in those aged over 64 years was 30%
among men and 35% among women (7). This higher
prevalence in aging populations over the past 40 years
has resulted in an increased population at risk of
nephropathy and ESRD.
There is also an increased tendency for these patients to
be referred for dialysis care and there are fewer restric-
tions on their dialysis programs. However, the 5-year
survival for patients with ESRD secondary to diabetes
mellitus is only 20 to 23% in Canada (1). Earlier
intervention to prevent the development and progression
of diabetic nephropathy may be more effective.
PREVENTION AND TREATMENT
OF DIABETIC NEPHROPATHY
(TYPE 1 DIABETES MELLITUS)
There is strong evidence that excellent glycemic control
(8) and the use of angiotensin converting enzyme
inhibitors (9) will decrease the probability of developing
diabetic nephropathy (8) and of doubling the serum
creatinine (9). There is less agreement about the role of
dietary protein restriction. The finding of increased
urinary albumin excretion when dietary protein exceeds
20% of energy intake (10) has led to the suggestion that
protein restriction be added to the prevention strategies
(11). The stages of diabetic nephropathy associated with
type 1 diabetes mellitus have traditionally been described
as hyperfunction, latency, microalbuminuria, macro-
albuminuria and ESRD (12). The interventions that
appear to be effective decrease glomerular hyperfiltration
and are associated with the first three stages. The
evidence that these same interventions will be effective
for those with type 2 diabetes mellitus is less clear.
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patients requiring photocoagulation. Macrovascular
complications were not reduced. However, the relative
risk of developing microalbuminuria was lower in the
intensive group (0.67; 95% CI 0.53-0.86), and the relative
risk of developing macroalbuminuria was decreased,
although not by a significant degree (0.66; 95% CI 0.39-
1.1). Although the number of affected individuals was
small, the relative risk of doubling the serum creatinine
was decreased in the intensive group over a 12-year
follow-up (0.26; 95% CI 0.07-0.91).
In a prospective observational study of 4585 patients in
the UKPDS (18), for each 1% reduction in the mean Hb
A1c, the relative risk for death related to diabetes
decreased by 21% and for myocardial infarction and
microvascular complications by 14% and 37%
respectively. The lowest risk was for patients with Hb
A1c lesser than 6%. The association of albuminuria and
renal function were not reported. These data support the
application of interventions that improve glycemic
control and normalize Hb A1c levels.
Treatment of hypertension
A recent consensus report recommended a target blood
pressure (BP) of 130/80 mmHg for patients with diabetes
and hypertension (19). The studies reviewed show an
association between a higher mean arterial pressure and
a greater rate of loss of renal function. For a mean arterial
pressure of 119 mmHg, the rate of loss of GFR was
12 mL/minute/year compared with 3 mL/minute/year if
the mean arterial pressure was 99 mmHg. However, these
studies included patients with both types of diabetes and
non-diabetic subjects. Other investigators have
specifically studied patients with type 2 diabetes (20-
22). The effect of angiotensin converting enzyme
inhibition has been studied in normotensive patients with
type 2 diabetes mellitus, microalbuminuria and a serum
creatinine less than 124 µmol/L (20). Patients were
randomly allocated to receive enalapril 10 mg daily or
placebo. The enalapril treated patients had no change in
urinary albumin excretion or serum creatinine over 5
years while the placebo treated group had an increase in
urine protein excretion from 123 to 310 mg per 24 hours
and a 13% decline in renal function.
In the UKPDS (21), 758 patients with newly diagnosed
type 2 diabetes were randomly allocated to tight blood
pressure control, 400 to receive angiotensin converting
enzyme inhibitors, 358 to receive beta blockers, and 390
to less aggressive BP control. Mean BP was 144/82 in
the tight and 154/87 in the less aggressive control group.
Glycemic control was similar. Aggressive blood pressure
control was associated with a decrease in the risk of death
associated with diabetes, stroke and microvascular
STAGES OF DIABETIC NEPHRO-
PATHY (TYPE 2 DIABETES MELLITUS)
The stages of diabetic nephropathy in type 2 diabetes
mellitus differ to those described in type 1. These
differences have been recently evaluated (6). When type
2 diabetes is diagnosed, the rate of hyperfiltration is half
than that seen in type 1, microalbuminuria is already
present in 15% and hypertension may be present. In stage
2 (latency), in addition to glomerular basement
membrane thickening and increased mesangial matrix,
vascular and chronic interstitial changes are common.
In stage 3, the presence of microalbuminuria is predictive
of cardio-vascular disease (in type 1 diabetes mellitus it
is more predictive of changes in glomerular filtration rate,
GFR). Stage 4 (macroalbuminuria) and stage 5 (ESRD)
diabetic nephropathy is similar for type 1 and 2 diabetes.
With the appearance of macroalbuminuria, the
cumulative incidence of ESRD among Caucasians is
about 70% over 15 years follow-up, similar to that
reported for Pima Indians with type 2 diabetes mellitus.
For Caucasians with type 2 diabetes mellitus, the
cumulative incidence of ESRD over 15 years is about
15%. This lower rate of ESRD among type 2 diabetic
Caucasians may be explained by the older age of onset
and greater cardiovascular mortality for Caucasians
compared with Pima Indians (6,13-15).
RISK FACTORS FOR THE DEVELOP-
MENT OF DIABETIC NEPHROPATHY
Studies of type 2 diabetes in the Pima Indian population
have yielded strong evidence for genetic risk factors.
Proteinuria developed in 14% of diabetic offspring when
neither parent had proteinuria, 23% if one parent had
proteinuria and 46% if both parents had diabetes and
proteinuria (16). Other potentially correctable clinical
risk factors include hypertension, poor glycemic control,
obesity and smoking habit (6).
PREVENTION AND TREATMENT
OF DIABETIC NEPHROPATHY
(TYPE 2 DIABETES MELLITUS)
Glycemic control
The role of glycemic control in preventing complications
was evaluated in 3867 patients with newly diagnosed
type 2 diabetes in the United Kingdom Prospective
Diabetes Study (UKPDS) (17). Patients were randomly
allocated to either conventional (diet) or intensive (diet
plus sulphonylurea or insulin) therapy. Over 10 years,
the hemoglobin (Hb) A1c value was 7% in the intensive
group compared with 7.9% in the conventional group.
There was a significant reduction in the risk of
microvascular complications, mostly due to fewer
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complications. However, there was little effect on
diabetic nephropathy. At 6 years follow-up, there was a
decreased relative risk for a urinary protein concentration
of greater than 50 mg/L in the aggressive control group
(RR 0.61; 95% CI 0.51-0.99) but no change in the risk
of developing macroalbuminuria or of doubling the
serum creatinine. This may have been due to inadequate
lowering of BP as 44% of the aggressive control group
had an average mean arterial pressure lower than 107
mmHg (23).
The Heart Outcomes Prevention Evaluation (HOPE)
Study evaluated the effects of ramipril on cardiovascular
and microvascular outcomes in 3577 patients with
diabetes mellitus (98% type 2) and at least one
cardiovascular risk factor (22). Although the risk
reductions for myocardial infarction, stroke and
cardiovascular death were significantly reduced, the
effect on diabetic nephropathy was less impressive. Over
4 to 5 years of follow-up, there was a 24% risk reduction
(95% CI 3-40%) for the development of proteinuria,
defined as a urinary albumin to creatinine ratio of over
36 mg/mmol.
In a Danish study (24) patients with type 2 diabetes
mellitus and microalbuminuria were randomized to
standard treatment or an intensive treatment regimen that
targeted hyperglycemia, hypertension, dyslipidemia and
behavior modification (smoking cessation and exercise).
Over a 4-year follow-up, the intensive therapy group had
a decreased risk for the development of macroalbumi-
nuria (odds ratio 0.27; 95% CI 0.1-0.75). The GFR
declined 13 and 11 mL/minute/1.73m2 over 4 years in
the standard and the intensive therapy groups res-
pectively.
These data indicate that strategies that aim to normalize
glycemia and control BP level to around 130/80, prefer-
ably with angiotensin converting enzyme inhibitors are
associated with significant decreases in mortality and
macrovascular complications associated with diabetes.
Behavioral interventions that encourage exercise, weight
reduction and smoking cessation appear to be logical.
The impact on diabetic nephropathy is less convincing.
The UKPDS study (17) suggests a benefit for aggressive
glycemic control in the prevention of diabetic
nephropathy although other studies have not confirmed
this (21,22). Ravid et al (20) demonstrated a beneficial
effect of angiotensin converting enzyme inhibition for
normotensive patients with microalbuminuria while
Gaede and colleagues (24) reported encouraging results
with a multifactorial intervention strategy with respect
to the development of macroalbuminuria. However,
the rate of loss of GFR was no different from that of
patients given standard therapy. If current strategies
are more effective in preventing macrovascular disease
than preventing diabetic nephropathy, the net result may
be a continued increase in the rate of ESRD due to
diabetes.
ALTERNATIVE STRATEGIES
An alternative is to target treatment at an earlier point in
the pathophysiologic process that leads to diabetic
nephropathy. Impaired endothelium-dependent vascular
responses in retinal and renal vessels have been
demonstrated in patients with type 2 diabetes mellitus
compared with normal controls. This impairment was
present in those with normal albumin excretion as well
as in those with microalbuminuria, although the
impairment was greater in the latter. Hyperhomo-
cystinemia has been associated with endothelial
dysfunction in patients with type 1 diabetes mellitus (26).
In type 2 diabetes mellitus it has been associated with
diabetic neuropathy and nephropathy (27). Patients with
type 2 diabetes mellitus have higher plasma homo-
cysteine concentrations than comparable patients
with type 1 diabetes and non-diabetics (28). In addition,
the urinary albumin excretion rate has a strong posit-
ive association with the plasma homocysteine con-
centration (29). If increased plasma homocysteine
is causally related to endothelial dysfunction that,
in turn, is responsible for microalbuminuria and
more advanced diabetic nephropathy, then strategies
that decrease homocysteine concentrations should be
logical.
CONCLUSIONS  AND PERSPECTIVES
A randomized clinical trial that compares a combination
of folic acid, pyridoxine and vitamin B12 with placebo
has received funding from the Canadian Institutes for
Health Research. It is thought that these vitamins should
decrease homocysteine levels because of their key roles
in homocysteine metabolism: folic acid is the substrate
for methyltetrahydrofolate reductase, pyridoxine is the
co-factor for cystathionine beta synthase and B12
for methionine synthase. The doses chosen, folic
acid 2.5 mg, pyridoxine 25 mg and Vitamin B12 1 mg,
have been shown to effectively reduce homocysteine
levels. It is hoped that a reduced homocysteine
levels will decrease endothelial dysfunction and
improve clinical outcomes. Three hundred patients
with diabetic nephropathy in three centres will
be randomly allocated to treatment or placebo groups
and followed up for 5 years. If effective, this low
cost therapy can become part of the multifactorial
approach to preventing progression of diabetic nephro-
pathy.
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